Table 2.

Key trials of platinum agents in advanced/metastastic BC with gBRCA1/2 mutations

Trial	Population	Phase	Treatment arms	Outcomes
TNT (NCT00532727) [46]	Advanced/metastatic TNBC	III	Carboplatin vs. docetaxel	Overall population: ORR 31.4% (carboplatin) vs. 34% (docetaxel); PFS 3.1 months (carboplatin) vs. 4.4 months (docetaxel); OS 3.1 months (carboplatin) vs. 4.4 months (docetaxel) gBRCA1/2 subgroup: ORR 68% (carboplatin) vs. 33% (docetaxel); PFS 12.8 months (carboplatin) vs. 12 months (docetaxel)
TBCRC009 (NCT00483223) [47]	Metastatic TNBC	II	Cisplatin vs. carboplatin	Overall population: ORR 25.6% (study population); ORR 32.6% (cisplatin) vs. 18.7% (carboplatin) gBRCA1/2 subgroup: ORR 54.6%

BC: breast cancer; gBRCA1/2: germline mutations in the BReast CAncer (BRCA) 1/2 gene; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TNBC: triple negative breast cancer